7.42 USD
↘ 0.32 (4.13%)AT CLOSE (11:59 AM EDT)
Arvinas, Inc
ARVNNASDAQ • USD
7.35
↘ 0.07 (0.96%)
POST MARKET (AS OF 07:58 PM EDT)
Post Market
AS OF 07:58 PM EDT
7.35
↘ 0.07 (0.96%)
Market: CLOSED
Open?$7.71
High?$7.81
Low?$7.40
Prev. Close?$7.74
Volume?650.0K
Avg. Volume?899.8K
VWAP?$7.56
Rel. Volume?0.72x
Bid / Ask
Bid?$7.19 × 100
Ask?$7.35 × 12.3K
Spread?$0.16
Midpoint?$7.27
Valuation & Ratios
Market Cap?478.7M
Shares Out?64.5M
Float?52.0M
Float %?80.6%
P/E Ratio?N/A
P/B Ratio?1.24
EPS?-$3.43
Dividend?0.00%
Ex-Dividend?N/A
Shares of Arvinas, Inc (ARVN) are trading at $7.42. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. This is driven by a concerning Altman Z-Score in the distress zone, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On valuation, ARVN trades roughly in line with sector averages — neither particularly cheap nor expensive.
Technical & fundamental data as of Jun 5, 2026.
News
Profile
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Themes
Employees
246
Market Cap
478.7M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2018-09-27
Address
395 WINCHESTER AVE
NEW HAVEN, CT 06511
Phone: 203-535-1456
NEW HAVEN, CT 06511
Phone: 203-535-1456
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?23
Z-Score?0
Momentum?50
Short Sent.?35
Piotroski F-Score?3/9Weak
Altman Z-Score?-2.71Distress
Confidence?63%Moderate
Short InterestElevated
Short % of Float?9.69%Elevated
Short Interest?5.0M
Days to Cover?4.4
Free Float52.0M
Avg Daily Volume1.1M
Settlement Date2026-05-15
Financial Health
Current Ratio?5.44Strong
Quick Ratio?5.44Strong
Cash Ratio?0.75Adequate
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score83/100
P/E?N/A▾
P/B?1.24CHEAP▾
Peers100
S&P92
P/S?5.36FAIR▾
Peers100
S&P26
P/FCF?N/A▾
EV/EBITDA?-1.6CHEAP▾
S&P97
EV/Sales?4.38FAIR▾
Peers100
S&P42
Returns & Efficiency
ROE?-57.2%WEAK▾
S&P3
ROA?-34.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-256900000
Enterprise Value?$391.7M
Fundamentals ratios updated end of day